NGVTNYSEChemicals & Allied ProductsFiscal year ends December 31
Ingevity Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$70.31+0.49 (+0.70%)
Close on Oct 19, 2026
- Market cap
- $2.48B
- P/E (TTM)
- 47.8
- Dividend yield
- –
Ingevity Corp revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PM | $606.90M | $609.60M | $586.00M | $548.50M | $516.80M | $510.00M | $490.60M | $400.40M | $349.30M | $301.00M | 52.0% | -0.4% |
| Performance Chemicals | $400.50M | $401.90M | $425.50M | $875.10M | $688.90M | $706.10M | $802.30M | $733.20M | $623.10M | $607.30M | 34.3% | -0.3% |
| APT | $160.20M | $188.60M | $204.00M | $244.70M | $185.80M | – | – | – | – | – | 13.7% | -15.1% |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PM | $326.30M | $333.20M | $303.10M | $252.20M | $249.40M | $249.20M | $213.40M | $169.40M | $141.80M | $106.90M | -2.1% |
| Performance Chemicals | $60.30M | $53.70M | $71.10M | $160.40M | $140.50M | $148.70M | $183.50M | $151.10M | $100.90M | $56.70M | +12.3% |
| APT | $32.10M | $39.00M | $49.00M | $40.00M | $32.30M | – | – | – | – | – | -17.7% |
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | $665.10M | $651.50M | $672.70M | $983.20M | $763.30M | $676.90M | $795.70M | $770.40M | $662.90M | $597.80M | 57.0% | +2.1% |
| United States | $585.00M | $571.50M | $602.30M | $897.10M | – | – | – | – | – | – | 50.1% | +2.4% |
| Asia Pacific | $298.50M | $325.00M | $323.30M | $398.70M | $385.50M | $345.40M | $281.40M | $171.40M | $142.50M | $138.80M | 25.6% | -8.2% |
| Europe, Middle East, and Africa | $158.90M | $172.40M | $179.90M | $242.20M | $219.60M | – | – | – | $149.20M | $151.10M | 13.6% | -7.8% |
| China | $153.10M | $175.60M | $189.20M | $220.60M | – | – | – | – | – | – | 13.1% | -12.8% |
| South America | $45.10M | $51.20M | $39.60M | $44.20M | $23.10M | $18.90M | $22.20M | $21.90M | $17.80M | $20.60M | 3.9% | -11.9% |
| Europe, Middle East, and Africa | – | – | – | $242.20M | $219.60M | $174.90M | $193.60M | $169.90M | $149.20M | $151.10M | – | – |
From the segment and revenue-disaggregation notes of Ingevity's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.